Introduction
Mass drug administration (MDA) is used to control many neglected tropical diseases (NTDs). This type of preventive chemotherapy targets all at-risk eligible individuals within defi ned age ranges. Although in 2012, 700 million people received at least one MDA round, this is only 36% of those in need of treatment.
1 Since the London declaration on NTDs in 2012, 2 the availability of donated drugs has dramatically increased and is no longer regarded as a major bottleneck to the control and elimination eff orts of the included NTDs. 3 However, the scaling up of the implementation of MDA programmes remains the key obstacle to reaching the 2020 targets set by WHO and the London declaration. [2] [3] [4] This issue with scaling up implementation is particularly true for the soil-transmitted helminths (STHs), for which WHO has set goals to scale up MDA, so that by 2020, 75% of preschool and school-age children in need will be treated regularly (ie, annually where prevalence is 20-50% or biannually where prevalence exceeds 50%). 2, 4 MDA programmes have benefi cial economies of scale 5-8 -increasing the number treated reduces the cost per treatment (panel). Such economies of scale arise because many of the costs associated with MDA are fi xed (ie, not dependent on the number treated) and therefore increasing the interventions output reduces the fi xed cost per treatment (panel). Furthermore, as programmes expand they are likely to become more effi cient through better organisation and learning by doing.
5, 12 Such economies of scale are not unique to MDA and can also occur for other interventions. 13 However, although accounting for economies of scale is recommended in economic assessments, 14, 15 because of the absence of detailed cost data, most studies assume constant returns to scale 12, [16] [17] [18] [19] -ie, the cost per treatment is constant, regardless of the number treated. Thus, with this assumption, the total cost of MDA would increase linearly with the number treated.
In view of this need to rapidly scale up MDA, [1] [2] [3] [4] understanding how the cost and cost-eff ectiveness of MDA programmes might be aff ected by these reported economies of scale, and assessment of the potential eff ect of ignoring them on policy recommendations, is important. We aimed to use a STH transmission model to compare use of a cost function to take into account economies of scale to the standard method of assuming a constant cost per treatment when investigating the cost and costeff ectiveness of scaling up a STH MDA programme targeting Ascaris lumbricoides.
Methods

Model
We used a fully age-structured model of the transmission dynamics of STHs for this analysis. 9, 10 In this analysis, we used the model parameters pertaining to A lumbricoides to act as a case study (appendix) .
We used the model to simulate a hypothetical district, with a total population of 200 000 individuals at risk of infection-chosen to take into account the full range of the cost data-and a school-based albendazole treatment pro gramme targeting school-age children (5-14 years old; about 32% of the total population). 9, 10 The assumed age distribution pertains to sub-Saharan Africa and is based on Uganda's demographic profi le. 20 As in previous analyses, 9 ,10 three diff erent transmission settings were investi gated-low (reproductive number [R 0 ]=2), medium (R 0 =3), and high (R 0 =5; panel). 21 These stratifi cations diff er from the WHO prevalence categories for reasons described by Truscott and colleagues. 9 The analysis was done by looking at one district to show the key principles clearly, although the conclusions would apply to national programmes as a whole.
Within the model, the number treated was varied by changing the treatment coverage of the school-age children at risk of infection within the district (panel). Based on the reported coverages from the districts where the cost data were collected, 5 a maximum coverage of 95% of school-age children was assumed within this analysisthe upper limit of the reported coverages. MDA does not include any previous diagnosis before treatment, so uninfected individuals would also be treated.
The effi cacy of albendazole against A lumbricoides, defi ned within the model as the proportion of worms expelled per treatment, was assumed to be 95%.
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Costs
We used a cost function that describes how the total cost per year of MDA changes with the number treated, g. Two terms exist within the function: α 1 , which represents the fi xed costs (ie, those that are incurred, and do not change, regardless of how many are treated), and α 2 , which represents the subsequent incremental cost per treatment
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Added value of this study
The aim of this analysis was to use a soil-transmitted helminths (STHs) transmission model-focusing on Ascaris lumbricoidesto investigate the eff ect of taking into account versus ignoring economies of scale on the costs and cost-eff ectiveness of scaling up a STH MDA programme. We investigated two assumptions: the commonly used constant cost per treatment and use of a cost function fi tted to empirical data on a MDA programme, taking into account economies of scale. When using this cost function, the projected cost-eff ectiveness of the STH control programme markedly increased as it was scaled up to treat more people. By contrast, assuming a constant cost per treatment (ie, the standard method) undervalued the cost-eff ectiveness of scaling up MDA programmes and generated some misleading conclusions.
Implications of all the available evidence
The analysis shows the fundamental importance that taking into account economies of scale can have in economic assessments, and how the common practice of ignoring this aspect can have a detrimental eff ect on the conclusions, potentially biasing policy. Although this study focused on MDA programmes for control of NTDs, the fi ndings are also relevant to the assessment of other large-scale control interventions that might have economies of scale, such as vaccination programmes, vitamin A distribution programmes, and malaria control.
See Online for appendix (ie, the variable cost). When deriving the cost per treatment from the cost function, the fi xed costs, α 1 , are divided by the number treated, g, which consequently decreases the cost per treatment with increasing numbers treated, taking into account potential economies of scale.
The cost function was fi tted to economic cost data collected as part of a school-based deworming pro gramme in Uganda. The data were collected across six districts over 3 years from the perspective of the service provider, since the costs of accessing the intervention are likely to be negligible. 5 The programme cost data were collected through semi-structured inter views with district offi cials and by detailed examination of the programme accounting records in six intervention districts in Uganda.
5 Both fi nancial and economic costs were collected; economic costs include the opportunity cost of using existing Ministry of Health staff and teachers. The delivery cost data are organised into fi ve main cost types: (1) programme running costs; (2) community awareness activities; (3) training of delivery staff ; (4) drug registration and distribution; and (5) production of information, education, and com munication material. 5 For this analysis, the unit cost of albendazole (400 mg) was assumed to be US$0·02 (2014 prices). 23 The fi tting of the cost function to the data was done using maximum likelihood methods (appendix).
The diff erent cost components of the intervention were identifi ed using an ingredients-based approach, taking into account both the number of units and the prices of units in the local currency (Ugandan Shillings). 5 The appendix includes a summary of the data. The costs presented in the study by Brooker and colleagues 5 were adjusted for infl ation using the gross domestic product implicit price defl ator and are expressed in US$ 2014 prices. 24 The cost function taking into account the economies of scale was compared with the standard method of assuming a constant cost per treatment, b, taken as the mean of the data range ($0·85, of which $0·83 is for delivery). 5 In this case, the total cost per year was derived by multiplying the number treated per year, g, by this constant cost per treatment, b. This calculation assumes constant returns to scale.
Implementation period and time horizon
WHO recommends that interventions are assessed using a 10-year implementation period.
14 However, this period refers only to the timeframe across which the intervention is implemented. The time horizon for the analysis (in this case 50 years) is longer to account for the full benefi ts of the intervention, which can occur both during and after its period of implementation. The mean number of female worm off spring generated by a female worm in the absence of density-dependent or mate-availability constraints.
Coverage
The proportion of the targeted population-in this case school-age children at risk of infection-that are treated each treatment round.
Discounting
The process of adjusting the future values of costs and eff ects to show that society prefers to receive benefi ts sooner and pay costs later. The discount rate shows the strength of this time reference.
Diseconomies of scale
The increase in the mean cost per unit of output resulting from increased production (ie, the opposite to economies of scale). This can result from programmes expanding into harder-to-reach areas, which can be more expensive.
Economies of scale
The reduction in the mean cost per unit of output resulting from increased production. In this case, it refers to the reduction in the cost per treatment of an intervention as a result of increasing the numbers treated.
Economies of scope
The reduction in the mean cost per unit resulting from production of two or more products at once. In this case, it refers to the reduction in the cost per treatment when delivering more than one intervention at once, such as when integrating diff erent control programmes.
Fixed costs
Costs that are not dependent on the quantity of output-ie, in this case, costs that are incurred or that do not change regardless of the number treated within a district. For example, many of the programme running costs at the national level would probably be incurred regardless of how many individuals are subsequently treated within any given district.
Force of infection
The mean number of incoming worms establishing per person per year-a metric for the level of ongoing transmission within the model.
Transmission breakpoint
The non-zero parasite density below which a parasite population cannot maintain itself and is driven into terminal decline and eventual elimination.
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Variable costs
Costs that vary in proportion to the quantity of the output-in this case costs that are dependent on the number treated. A key variable cost is that of the total cost of the drugs themselves, which would depend directly on the number of treatments given.
Information based on Turner and colleagues. 8 The cost-eff ectiveness ratios (ie, the cost per unit of eff ect) were derived by dividing the total cost accrued during the implementation period by the total eff ects accumulated across the full time horizon.
These guidelines 14 are based on the assessment of morbidity control strategies. However, elimination strategies, which aim to stop transmission and make future control measures unnecessary, might need a longer timeframe to account for their long-term benefi cial eff ects. 25 Therefore, within a subset of our simulations, we also considered a longer implementation period of 35 years. Our simulation model includes the eff ects of sexual reproduction and, as a result, elimination is a deterministically defi nable event. 21 Elimination has been achieved when mean worm burdens have fallen below a crucial threshold or, equivalently, the parasite burden continues to fall to zero in the absence of treatment. As recommended by WHO, 14 a discount rate of 3% was applied to both the costs and eff ects (panel). The sensitivity of the results to both the use of a 0% discount rate for eff ects and a rate of 6% for the costs was explored, based on WHO-Choice guide lines.
14 Because the eff ects and costs are still being discounted (panel) at 3% per year and are only taken into account within the 50-year time horizon, the projected benefi ts of elimination are not infi nite.
Eff ectiveness metrics
The model was used to investigate three diff erent eff ectiveness metrics (modifi ed from Medley and colleagues 26 ) across the chosen time horizon: (1) the total number of worm-years averted (ie, the number of years lived with a worm prevented); (2) the total number of prevalent infection case-years averted (ie, the number of years lived with a prevalent infection prevented); and (3) the total number of heavy infection case-years averted (ie, the number of years lived with a heavy infection prevented). Heavy burden was defi ned as having a worm burden above the age-specifi c thresholds for disease presented by Chan and colleagues 27 (appendix). For each year, we calculated the eff ectiveness as the diff erence between the worm burden or number of cases and the number in absence of treatment (appendix).
Role of the funding source
The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had fi nal responsibility for the decision to submit for publication.
Results
The cost function taking into account the economies of scale accounted well for the noted patterns in the cost data (fi gure 1). By contrast, the standard method of assuming a constant cost per treatment did not correspond well to the data; it substantially underestimated the total cost per year of treating a small number of individuals and overestimated the total cost per year of treating a large number of individuals (fi gure 1A).
When using the cost function taking into account the economies of scale, the projected cost-eff ectiveness of MDA increased substantially as the number of at-risk school-age children treated within the district was scaled up. This pattern occurred because as treatment was scaled up, the increase in cost derived from the cost function (fi gure 1A) was smaller than the projected increase in the eff ects (fi gure 2A-C). As such, the cost-eff ectiveness ratio (ie, the cost per eff ect) decreased (fi gure 2D-F). This decrease resulted in an increase in the cost-eff ectiveness of controlscaling up control from 10% to 75% coverage of at-risk school-age children within our projected district increased the cost-eff ectiveness in terms of preventing heavy infections by over 70% (appendix). Because an assumed incremental cost per treatment is included within the cost function, the gain in cost-eff ectiveness with scale showed some diminishing returns and approached a maximum level, because the cost per treatment cannot decrease past the assumed incremental cost per treatment, α 2 (fi gure 1B). By contrast, when the economies of scale were ignored and a constant cost per treatment was assumed-the standard method-the projected cost-eff ectiveness remained relatively constant when scaling up treatment (fi gure 2D-F); it only increased slightly in terms of the cost per prevalent case-year averted (fi gure 2E) and even decreased in terms of the cost per heavy case-year averted (fi gure 2F). Thus, this standard assumption incorrectly undervalued the cost-eff ectiveness of scaling up MDA because, when assuming the cost per treatment is constant, the total cost per year increased linearly with the number treated (fi gure 1A). Consequently, when scaling up treatment, the increase in both the eff ects (fi gure 2) and costs were similar, hence the ratio of the two remained constant. The cost-eff ectiveness in terms of prevalent case-years and heavy case-years averted (fi gure 2E and 3F) changed with scale, because of the non-linear gain in eff ects as the coverage of at-risk school-age children increased (fi gure 2B and 2C). D-F) the smaller the cost-eff ectiveness ratio, the more cost eff ective mass drug administration is deemed to be. Results assume a 50-year time horizon, a period of implementation of 10 years (ie, ten annual treatment rounds), a 3% discount rate, and a total population size of 200 000 individuals, 32% of whom were SAC. SAC=school-age children. Results assume a 10-year implementation period (ie, up to ten annual treatment rounds), a 50-year timeframe, and 75% coverage.
Table:
The sensitivity of the total eff ectiveness to the assumed transmission setting
The total eff ectiveness of the intervention in terms of the overall reduction in worm burden and the number of heavy case-years averted-both metrics that are based on infection intensity-increased with the assumed level of pre-control endemicity or transmission intensity (table) . By contrast, the total number of prevalent case-years averted-a measure based only on infection prevalencedecreased as the transmission intensity increased (table) . This situation arose because of the non-linear relation between mean worm burden and prevalence (fi gure 3A), created by aggregated distributions of worm numbers (a large proportion of worms were in a small proportion of individuals); thus, at higher worm burdens, large changes in mean worm burden are likely to lead to only small changes in prevalence (fi gure 3A). Furthermore, annual treatment of school-age children only is not always eff ective in terms of reducing the overall level of transmission within the population. This fi nding is shown by looking at the eff ect of control on the local force of infection (panel)-a measure of transmission-which decreased as the assumed level of transmission intensity was increased (fi gure 3B).
Because of these relations, the higher the transmission intensity, the higher the cost-eff ectiveness of the intervention in terms of the reduction in the overall worm burden and heavy infections averted (fi gure 2D and 2F). However, counterintuitively, the cost-eff ectiveness in terms of the number of prevalent case-years averted was higher the lower the level of transmission intensity (fi gure 2E).
The increase in cost-eff ectiveness in terms of heavy infections averted as the level of assumed transmission intensity was increased shows some diminishing returns (table) . This fi nding occurred because in high-transmission settings, treatment of school-age children only does not eff ectively control the number of heavy infections.
When we included a longer implementation period in areas with low transmission intensity (ie, 35 years instead of 10 years), the benefi ts of elimination within the 50-year time horizon of the analysis became apparent (fi gure 4). The potential for local elimination by chemotherapy alone is theoretically possible when worm levels become low enough for no one individual to harbour both a male and female worm, which means eggs are unfertilised and transmission is broken-ie, a transmission breakpoint (panel). Under these circum stances, the costeff ective ness increased at a faster rate as the coverage was scaled up (fi gure 4A). This fi nding occurred because, after elimination is achieved, the costs of future control are avoided. As coverage is increased, the time to elimination is reduced, generating a lower total cost (fi gure 4B). When falsely assuming a constant cost per treatment-the standard assumption-the total cost of scaling up control was overestimated (fi gure 4B).
Varying the discount rate had little eff ect on the projected cost-eff ectiveness of control (appendix) and the general conclusions remain unchanged. However, the choice of the discount rate for the costs had implications regarding the potential cost savings generated by reaching elimination (appendix); the higher the discount rate, the lower the potential cost savings.
Discussion
Because of economies of scale, the cost per treatment of MDA decreased with increasing numbers treated. Consequently, projected cost-eff ectiveness of STH control programmes markedly increased as they were scaled up to treat more at-risk school-age children. Although this analysis was done by investigating one district targeting primarily A lumbricoides as a case study, these conclusions can be applied more generally to national STH programmes. This increase in costeff ectiveness has important impli cations for countries and donors that are con sidering scaling up MDA in line with the targets set by the WHO and the London declaration (appendix).
2,4
These results also have implications for MDA resource allocation for other NTDs that do not have widespread control.
By contrast, the standard method of assuming a constant cost per treatment undervalued the cost-eff ective ness of scaling up MDA and might even in correctly generate misleading conclusions. For example, when scaling up control in the projected district from 10% to 75% coverage of at-risk school-age children, the cost-eff ectiveness in terms of preventing heavy infections was projected to increase by over 70% when using the cost function, but decrease by 18% when assuming a constant cost per treatment (appendix). This analysis shows the fundamental importance taking into account economies of scale can have in economic assessments, and how ignoring this aspect, which is done in most economic assessments, can have a detrimental eff ect on con clusions, potentially incorrectly aff ecting policy. 28 This fi nding is particularly relevant to NTDs because of the nature of the costs of MDA-many of which are fi xed, because the drugs themselves are often donated or inexpensive-but is also relevant to other large-scale control programmes. 13 This research generated two other important conclusions for resource allocation and programme planning. First, accounting for economies of scale when comparing the reported costs of diff erent alternative strategies is essential, since if ignored analyses might lead to incorrect assumptions regarding the relative costs of diff erent strategies, and concomitantly might lead to the use of suboptimum policies for MDA imple men tation. 29 Second, use of models that account for the transmission dynamics of the parasite under MDA in any economic assessment, which can take into account the indirect eff ects of interventions, is desirable, as opposed to static models. 30 Within this analysis, the potential costs and eff ects of expanding the coverage of school-age children beyond 95% were not considered, because the coverage would need to be extrapolated beyond the range of the data used to parameterise the cost function. 5 In future studies, the potential increase in costs and diseconomies of scale (panel) 13, 31, 32 will be analysed as programmes are expanded to cover harder-to-reach groups (eg, schools in remote areas and school-age children who do not attend the treatment days). The strength of these diseconomies of scale and the point at which they start to apply within a control programme will vary in diff erent areas, which is likely to have implications regarding the costs to achieve elimination and the most cost-eff ective strategy. As such, more detailed studies and cost of control measurements are needed in these groups.
In the modelled scenarios, elimination with a schoolbased strategy was only possible in areas with low transmission intensity. To achieve elimination in areas with medium-to-high transmission requires an expansion of control beyond school-age children to include preschool and adults or an increased treatment frequency, or both. 9, 10 Although treatment of adults is likely to be more expensive initially, it will reduce the duration of programme needed, which ultimately is likely to lead to cost savings. 33 In this analysis, we focused only on A lumbricoides to act as a case study. One should note that there remains uncertainty surrounding the parameterisation of the key epidemiological processes of STH transmission models. However, the fi ndings presented regarding the increase in cost-eff ectiveness preliminarily arose because of the non-linearity in the costs, and therefore these results are directly relevant to the other STHs (eg, hookworm and trichuris) and parameter estimates. However, elimination of hookworm and trichuris would not be possible in most settings with only an annual treatment programme targeting school-age children, because for hookworm most worms are harboured by adults, and for trichuris the treatment effi cacy of albendazole is lower than for A lumbricoides. 9, 10, 22 Consequently, treatment of school-age children alone does not have as marked an eff ect on transmission compared with A lumbricoides.
The presented cost function relates only to a programme targeting only school-age children once per year. More cost functions were not explored because the dataset by Brooker and colleagues 5 was the only relevant one that could be identifi ed for a STH programme. 8 These results highlight the need for further cost data to be collected so that more comprehensive cost functions or predictive costing models can be developed to represent a range of diff erent settings, strategies, and potential diseconomies of scale. 13, 31, 32 These should be able to account for the potential diff erence between expansion of control by increasing coverage within a district, as shown herein, and expansion to new districts, because these are likely to have diff erent economies and diseconomies of scale. These cost functions should also include potential economies of scope (panel)-ie, how integration of diff erent control programmes might yield lower costs per treatment. 6 The absence of cost data for preschool children and adults constitutes a major barrier for further research regarding how best to optimise STH control and the development of further cost functions for the diff erent strategies.
A further need is for the STH specialty to decide which are the best eff ectiveness metrics by which to judge diff erent control strategies, since this is crucial when establishing the choice of intervention. 8, 34, 35 Within this debate, consideration of how diff erent programmatic objectives might need diff erent eff ectiveness metrics will be important.
This work further shows that when interventions are aimed at reducing morbidity, their eff ectiveness metric should be based on infection intensity and not simply prevalence. Basing the eff ectiveness metric on prevalence in this context can produce counterintuitive and misleading conclusions, showing treatment to be more cost-eff ective in lower versus higher transmission areas, which poorly represents the eff ect of treatment on disease burden, which is related to heavy infections. This fi nding was also reported by Guyatt and colleagues. 34 The best metric for assessment of the eff ect on morbidity within models might be heavy case-years averted, which can take into account the fact that a certain worm burden can have diff erent health consequences depending on the host's age-just looking at the overall reduction in worm burden does not account for this. However, the numerical thresholds at which worms cause disease are surrounded with uncertainty, and probably depend on several host-specifi c factors. 35 Furthermore, translating egg counts-how intensity is measured in practice-to number of worms can be diffi cult. 36 By contrast, when assessing interventions aimed at reducing transmission, metrics based on morbidity or heavy infections will be misleading, undervaluing the potential need to expand treatment to other age groups or increase the treatment frequency to reduce transmission.
These results support those of previous modelling studies [9] [10] [11] that showed that when the programmatic aim is to reduce transmission, as opposed to morbidity, targeting school-age children alone is unlikely to be suffi cient to achieve the desired results. [9] [10] [11] 33, 37 
